Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sarepta Therapeutics (NASDAQ:SRPT), a leader in precision genetic medicine for rare diseases, has granted equity awards to 28 new employees hired in September 2024. The awards, approved by the Compensation Committee under the company's 2024 Employment Commencement Incentive Plan, include a total of 23,580 restricted stock units (RSUs). These RSUs will vest over four years, with one-fourth vesting annually on the grant date anniversary, subject to continued employment. The grants were made in accordance with Nasdaq Listing Rule 5635(c)(4) as a material inducement to employment.
Sarepta, focused on developing treatments for Duchenne muscular dystrophy (DMD) and limb-girdle muscular dystrophies (LGMDs), currently has over 40 programs in various stages of development. The company's pipeline is driven by its multi-platform Precision Genetic Medicine Engine in gene therapy, RNA, and gene editing.
Sarepta Therapeutics (NASDAQ:SRPT), leader nella medicina genetica di precisione per malattie rare, ha concesso premi azionari a 28 nuovi dipendenti assunti a settembre 2024. I premi, approvati dal Comitato per la Compensazione nell'ambito del Piano di Incentivazione all'Inizio dell'Occupazione 2024 dell'azienda, includono un totale di 23.580 unità di azioni riservate (RSUs). Queste RSUs si matureranno in quattro anni, con un quarto che matura annualmente all'anniversario della data di concessione, soggetto a un'occupazione continuativa. Le concessioni sono state effettuate in conformità con la Regola 5635(c)(4) di Nasdaq come incentivo materiale all'occupazione.
Sarepta, impegnata nello sviluppo di trattamenti per la distrofia muscolare di Duchenne (DMD) e le distrofie muscolari a cintura (LGMD), ha attualmente oltre 40 programmi in vari stadi di sviluppo. Il pipeline dell'azienda è guidato dal suo motore di Medicina Genetica di Precisione multi-piattaforma nella terapia genica, RNA e editing genetico.
Sarepta Therapeutics (NASDAQ:SRPT), líder en medicina genética de precisión para enfermedades raras, ha otorgado premios de capital a 28 nuevos empleados contratados en septiembre de 2024. Los premios, aprobados por el Comité de Compensación bajo el Plan de Incentivo para el Inicio de Empleo 2024 de la empresa, incluyen un total de 23,580 unidades de acciones restringidas (RSUs). Estas RSUs se adquirirán a lo largo de cuatro años, con un cuarto que se adquiere anualmente en el aniversario de la fecha de concesión, sujeto a empleo continuo. Las concesiones se realizaron de acuerdo con la Regla de Inclusión 5635(c)(4) de Nasdaq como un inducimiento material para el empleo.
Sarepta, centrada en el desarrollo de tratamientos para la distrofia muscular de Duchenne (DMD) y las distrofias musculares de cintura (LGMD), actualmente tiene más de 40 programas en diversas etapas de desarrollo. La cartera de la empresa está impulsada por su motor de Medicina Genética de Precisión multi-plataforma en terapia génica, ARN y edición genética.
Sarepta Therapeutics (NASDAQ:SRPT)는 희귀 질병을 위한 정밀 유전 의학의 선두주자로서 2024년 9월에 채용된 28명의 신규 직원에게 주식 보상을 부여했습니다. 이 보상은 회사의 2024년 고용 시작 인센티브 계획에 따라 보상 위원회에서 승인된 것으로, 총 23,580개의 제한된 주식 단위(RSUs)가 포함되어 있습니다. 이 RSUs는 4년에 걸쳐 발생하며, 그 중 1/4은 부여일 기념일마다 매년 발생하며, 지속적인 고용을 조건으로 합니다. 이러한 부여는 나스닥 상장 규칙 5635(c)(4)에 따라 고용에 대한 물질적 유인으로 시행되었습니다.
Sarepta는 뒤센ne 근육 위축증(DMD) 및 사지띠 근육 위축증(LGMD)의 치료제를 개발하는 데 주력하고 있으며, 현재 각기 다른 개발 단계에 있는 40개 이상의 프로그램을 보유하고 있습니다. 회사의 파이프라인은 유전자 치료, RNA 및 유전자 편집 분야의 다중 플랫폼 정밀 유전 의학 엔진에 의해 추진됩니다.
Sarepta Therapeutics (NASDAQ:SRPT), un leader dans la médecine génétique de précision pour les maladies rares, a attribué des récompenses en actions à 28 nouveaux employés recrutés en septembre 2024. Les récompenses, approuvées par le Comité de Rémunération dans le cadre du Plan d'Incitation au Début de l'Emploi 2024 de l'entreprise, comprennent un total de 23 580 unités d'actions restreintes (RSUs). Ces RSUs s'échelonneront sur quatre ans, avec un quart s'échelonnant chaque année à l'anniversaire de la date d'attribution, sous réserve d'un emploi continu. Les attributions ont été réalisées conformément à la Règle d'Inclusion 5635(c)(4) de Nasdaq comme incitation matérielle à l'emploi.
Sarepta, axée sur le développement de traitements pour la dystrophie musculaire de Duchenne (DMD) et les dystrophies musculaires à ceinture (LGMD), a actuellement plus de 40 programmes à divers stades de développement. Le pipeline de l'entreprise est soutenu par son moteur de Médecine Génétique de Précision multi-plateforme en thérapie génique, ARN et édition génétique.
Sarepta Therapeutics (NASDAQ:SRPT), ein führendes Unternehmen in der Präzisionsgenetik für seltene Krankheiten, hat Aktienvergütung an 28 neue Mitarbeiter ausgegeben, die im September 2024 eingestellt wurden. Die Prämien, die vom Vergütungsausschuss im Rahmen des Beschäftigungsanfangs-Incentive-Plans 2024 des Unternehmens genehmigt wurden, umfassen insgesamt 23.580 beschränkte Aktieneinheiten (RSUs). Diese RSUs werden über vier Jahre hinweg fällig, wobei ein Viertel jährlich am Jahrestag des Zuteilungstages fällig wird, vorausgesetzt, dass das Beschäftigungsverhältnis fortbesteht. Die Zuteilungen wurden gemäß der Nasdaq-Listing-Regel 5635(c)(4) als wesentliche Anreize für eine Anstellung vorgenommen.
Sarepta, das sich auf die Entwicklung von Therapien für die Duchenne-Muskeldystrophie (DMD) und die Hüftentyphen-Muskeldystrophien (LGMDs) konzentriert, verfügt derzeit über mehr als 40 Programme in verschiedenen Entwicklungsstadien. Die Pipeline des Unternehmens wird von seiner Multi-Plattform-Engine für präzise genetische Medizin in der Gentechnologie, RNA und Genbearbeitung angetrieben.
- Granted equity awards to 28 new employees, potentially attracting and retaining talent
- Maintains leadership positions in Duchenne muscular dystrophy (DMD) and limb-girdle muscular dystrophies (LGMDs)
- Has over 40 programs in various stages of development, indicating a robust pipeline
- None.
The employees received in the aggregate 23,580 restricted stock units (“RSUs”). One-fourth of the RSUs will vest yearly on each anniversary of the Grant Date, such that the RSUs granted to each employee will be fully vested on the fourth anniversary of the Grant Date, in each case, subject to each such employee’s continued employment with Sarepta on such vesting date. Employees did not receive options to purchase shares of Sarepta’s common stock.
About Sarepta Therapeutics
Sarepta is on an urgent mission: engineer precision genetic medicine for rare diseases that devastate lives and cut futures short. We hold leadership positions in Duchenne muscular dystrophy (DMD) and limb-girdle muscular dystrophies (LGMDs), and we currently have more than 40 programs in various stages of development. Our vast pipeline is driven by our multi-platform Precision Genetic Medicine Engine in gene therapy, RNA and gene editing. For more information, please visit www.sarepta.com or follow us on LinkedIn, X (formerly Twitter), Instagram and Facebook.
Internet Posting of Information
We routinely post information that may be important to investors in the 'For Investors' section of our website at www.sarepta.com. We encourage investors and potential investors to consult our website regularly for important information about us.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240930826060/en/
Investor:
Ian Estepan, 617-274-4052
iestepan@sarepta.com
Media:
Tracy Sorrentino, 617-301-8566
tsorrentino@sarepta.com
Source: Sarepta Therapeutics, Inc.
FAQ
How many restricted stock units (RSUs) did Sarepta Therapeutics (SRPT) grant to new employees in September 2024?
What is the vesting schedule for the RSUs granted by Sarepta Therapeutics (SRPT) on September 30, 2024?
Under which Nasdaq rule did Sarepta Therapeutics (SRPT) approve the equity awards?
How many programs does Sarepta Therapeutics (SRPT) currently have in development?
